Depression
Conditions
Keywords
depression, antidepressant, resistance
Brief summary
According to the WHO, major depressive disorders have become the second worldwide cause of disability. Treatment, long-term medication, leads to frequent resistance (up to 40%). Establishing a cerebral molecular signature of depression is not feasible in humans (need for cerebral samples). The alternative is to use peripheral biological samples (blood, urine, saliva). Metabolomic is the integrated and quantitative study of all the metabolites of a biological system. This aims to define the metabolic status of an organism for a particular condition. Metabolites are derived from biological extracts (cells, tissues, serum, plasma, urine, etc.) and are detected by: * liquid or gas chromatography coupled to mass spectrometry (LC-MS, GC-MS), * proton nuclear magnetic resonance (1 H-NMR). The biomarkers resulting from these studies have become important diagnostic criteria, measured objectively and evaluated as indicators of a normal or pathological state, or even predictors of treatment efficacy. This approach allows the discovery of biomarkers that best describe the status of a disease for better understanding and are usable in a context of individualized medicine, with effects on clinical practice and management.
Interventions
OTHERolfactive tests
olfactive tests: odor identification, odor discrimination and olfactory threshold
BIOLOGICALblood test
one sample of 4mL
BIOLOGICALCollection of faeces
Collection of faeces by patient at home - optional
DEVICETissue Pulsatility imaging
Ultrasound exploration of brain pulsatility - optional
Sponsors
University Hospital, Tours
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* between 18-60 years-old * major depressive disorder, confirmed by Mini International Neuropsychiatric Interview (MINI) * no bipolar disorder or schizophrenia, confirmed by MINI * no neurological dementia disease * able to perform olfactive tests, i.e. no anosmia and/or allergy to odors * score MADRS (Montgomery AsbergDepression Rating Scale) \>20 * no antidepressant treatment during 14 days before inclusion * informed written consent * affiliation to a social security system
Exclusion criteria
* patient who don't want any antidepressant treatment for this depressive episode * legal incapacity and/or any circumstances making the person unable to understand the trial features, purposes or consequences * participating to drug clinical study or in exclusion period of clinical study because of previous participation * pregnant woman
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| metabolic print of blood | 2 months | Metabolome of blood |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| olfactive discrimination | 2 months | Olfactive response: odor discrimination |
| Olfactory threshold | 2 months | Olfactive response: olfactory threshold |
| Microbiote of faeces | 2 months | Bacteria of faeces |
| olfactive identification | 2 months | Olfactive response: odor identification |
| Mean measures of brain pulsatility | 2 months | Mean brain pulsatility |
| Metabolic print of faces | 2 months | Metabolome of faeces |
| Maximal measures of brain pulsatility | 2 months | Maximal brain pulsatility |
Countries
France
Outcome results
None listed